Gilenya vs Tysabri
Side-by-side cost comparison based on Medicare Part D data
Gilenya
Fingolimod
Manufactured by Novartis
Tysabri
Natalizumab
Manufactured by Biogen
Gilenya costs 42% less per claim than Tysabri ($5,738.00 vs $9,952.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Gilenya | Tysabri |
|---|---|---|
| Avg Cost Per Claim | $5,738.00 | $9,952.00 |
| Total Medicare Spending | $1.4B | $1.2B |
| Total Beneficiaries | 22,000 | 11,000 |
| Total Claims | 248,000 | 124,000 |
| Annual Cost/Patient | $64,682.00 | $112,182.00 |
| Year-over-Year Change | -14.8% | -3.2% |
| Generic Available | No | Yes |
| Patent Expiration | Sep 22, 2027 | Jan 31, 2023 |
| Manufacturer | Novartis | Biogen |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Fingolimod | Natalizumab |
Gilenya vs Tysabri: What the Data Shows
Gilenya (Fingolimod) and Tysabri (Natalizumab) are both used to treat multiple sclerosis. Based on Medicare Part D data, Gilenya costs $5,738.00 per claim, which is 42% less than Tysabri at $9,952.00 per claim.
Medicare spent $1.4B on Gilenya and $1.2B on Tysabri. In terms of patient reach, Gilenya serves more beneficiaries (22,000 vs 11,000).
Year-over-year spending changed -14.8% for Gilenya and -3.2% for Tysabri.
Tysabri has a generic available, while Gilenya remains brand-only until its patent expires Sep 22, 2027.
Frequently Asked Questions
Gilenya is cheaper at $5,738.00 per claim, compared to $9,952.00 for Tysabri. That makes Gilenya about 42% less expensive per claim based on Medicare Part D data.
Yes, both Gilenya and Tysabri are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Tysabri has a generic version (Natalizumab) available, which is typically much cheaper. Gilenya is currently brand-only, with patent expiring Sep 22, 2027.
Medicare Part D spent $1.4B on Gilenya covering 22,000 beneficiaries, and $1.2B on Tysabri covering 11,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.